About Vividion Therapeutics
Vividion Therapeutics is a company based in Oceanside (United States) founded in 2016 was acquired by Bayer in August 2021.. Vividion Therapeutics has raised $270.5 million across 4 funding rounds from investors including Bayer, ARE and Mirae Asset. The company has 123 employees as of December 31, 2021. Vividion Therapeutics has completed 1 acquisition, including Tavros. Vividion Therapeutics offers products and services including Chemoproteomics Platform and Drug Candidates. Vividion Therapeutics operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Cyrus Biotechnology and Korro Bio, among others.
- Headquarter Oceanside, United States
- Employees 123 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vividion
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vividion Therapeutics
Vividion Therapeutics offers a comprehensive portfolio of products and services, including Chemoproteomics Platform and Drug Candidates. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform identifies novel therapeutic targets in human proteome for disease treatment
Candidates evaluated in clinical trials for advanced solid tumors
Unlock access to complete
Unlock access to complete
Leadership Team
46 people
Principal Team
14 people
Senior Team
8 people
Scientist Team
7 people
Product Management Team
6 people
Operations Team
6 people
Software Development Team
5 people
Finance and Accounting
4 people
Unlock access to complete
Funding Insights of Vividion Therapeutics
Vividion Therapeutics has successfully raised a total of $270.5M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $135 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $135.0M
-
First Round
First Round
(31 Mar 2016)
- Investors Count 21
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2021 | Amount | Series C - Vividion Therapeutics | Valuation | Logos , Boxer Capital | |
| Apr, 2019 | Amount | Series B - Vividion Therapeutics | Valuation | Nextech Invest | |
| Jan, 2017 | Amount | Series A - Vividion Therapeutics | Valuation | Arch Venture Partners , Versant Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Vividion Therapeutics
Vividion Therapeutics has secured backing from 22 investors, including venture fund and institutional investors. Prominent investors backing the company include Bayer, ARE and Mirae Asset. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity fund focused on the biotechnology sector
|
Founded Year | Domain | Location | |
|
Biotech startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on biotechnology startups
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Vividion Therapeutics
Vividion Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tavros. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small-molecule therapeutics for cancer are developed via functional genomics.
|
2019 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Vividion Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vividion Therapeutics Comparisons
Competitors of Vividion Therapeutics
Vividion Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Cyrus Biotechnology and Korro Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Cloud-based protein-modeling software is developed for drug discovery.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vividion Therapeutics
Frequently Asked Questions about Vividion Therapeutics
When was Vividion Therapeutics founded?
Vividion Therapeutics was founded in 2016.
Where is Vividion Therapeutics located?
Vividion Therapeutics is headquartered in Oceanside, United States. It is registered at Oceanside, California, United States.
Is Vividion Therapeutics a funded company?
Vividion Therapeutics is a funded company, having raised a total of $270.5M across 4 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on Mar 31, 2016.
How many employees does Vividion Therapeutics have?
As of Dec 31, 2021, the latest employee count at Vividion Therapeutics is 123.
What does Vividion Therapeutics do?
Vividion Therapeutics is a stealth mode biotech company spun out from the Scripps Research Institute. The company was launched based on a small-molecule drug discovery platform assembled from the research of three prominent scientists from Scripps Research Institute. Vividion combines a proteome-wide ligand and target discovery platform from Benjamin F. Cravatt, co-chair of Scripps department of molecular medicine, with synthetic chemistry from the labs of professors Phil S. Baran and Jin-Quan Yu. Vividion has spent two years validating its approach in prototypic cells. Although the company has not yet disclosed targets, preclinical candidates, or disease focus, the company has assembled intellectual property around previously unrecognized, but druggable, sites in the human proteome.
Who are the top competitors of Vividion Therapeutics?
Vividion Therapeutics's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
What products or services does Vividion Therapeutics offer?
Vividion Therapeutics offers Chemoproteomics Platform and Drug Candidates.
How many acquisitions has Vividion Therapeutics made?
Vividion Therapeutics has made 1 acquisition, including Tavros.
Who are Vividion Therapeutics's investors?
Vividion Therapeutics has 22 investors. Key investors include Bayer, ARE, Mirae Asset, Citadel, and Mubadala.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.